83 related articles for article (PubMed ID: 21734071)
1. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
Drury SC; Detre S; Leary A; Salter J; Reis-Filho J; Barbashina V; Marchio C; Lopez-Knowles E; Ghazoui Z; Habben K; Arbogast S; Johnston S; Dowsett M
Endocr Relat Cancer; 2011 Oct; 18(5):565-77. PubMed ID: 21734071
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.
Winder T; Giamas G; Wilson PM; Zhang W; Yang D; Bohanes P; Ning Y; Gerger A; Stebbing J; Lenz HJ
Pharmacogenomics J; 2014 Feb; 14(1):28-34. PubMed ID: 23459444
[TBL] [Abstract][Full Text] [Related]
3. Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.
Wang T; Heng YJ; Baker GM; Bret-Mounet VC; Quintana LM; Frueh L; Hankinson SE; Holmes MD; Chen WY; Willett WC; Rosner B; Tamimi RM; Eliassen AH
Cancer Epidemiol Biomarkers Prev; 2022 Oct; 31(10):1926-1934. PubMed ID: 35914729
[TBL] [Abstract][Full Text] [Related]
4. The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients.
Zamzam Y; Abdelmonem Zamzam Y; Aboalsoud M; Harras H
Int J Surg Oncol; 2021; 2021():9947540. PubMed ID: 34567804
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction.
Baneshi MR; Warner P; Anderson N; Edwards J; Cooke TG; Bartlett JM
Br J Cancer; 2010 May; 102(10):1503-10. PubMed ID: 20461093
[TBL] [Abstract][Full Text] [Related]
6. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Saal LH; Johansson P; Holm K; Gruvberger-Saal SK; She QB; Maurer M; Koujak S; Ferrando AA; Malmström P; Memeo L; Isola J; Bendahl PO; Rosen N; Hibshoosh H; Ringnér M; Borg A; Parsons R
Proc Natl Acad Sci U S A; 2007 May; 104(18):7564-9. PubMed ID: 17452630
[TBL] [Abstract][Full Text] [Related]
7. Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer.
Zboril EK; Grible JM; Boyd DC; Hairr NS; Leftwich TJ; Esquivel MF; Duong AK; Turner SA; Ferreira-Gonzalez A; Olex AL; Sartorius CA; Dozmorov MG; Harrell JC
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370789
[TBL] [Abstract][Full Text] [Related]
8. Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.
Bergman R; Berko YA; Sanchez V; Sanders ME; Gonzalez-Ericsson PI; Arteaga CL; Rexer BN
Breast Cancer Res Treat; 2023 Jan; 197(2):307-317. PubMed ID: 36396775
[TBL] [Abstract][Full Text] [Related]
9. HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer.
Kim CY; Kim YC; Oh JH; Kim MH
J Cancer; 2021; 12(15):4626-4637. PubMed ID: 34149926
[TBL] [Abstract][Full Text] [Related]
10. Increased PI3K pathway activity is associated with recurrent breast cancer in patients with low and intermediate 21-gene recurrence score.
Lin LH; Wesseling-Rozendaal Y; Vasudevaraja V; Shen G; Black M; van Strijp D; Neerken S; van de Wiel PA; Jour G; Cotzia P; Darvishian F; Snuderl M
J Clin Pathol; 2024 Feb; ():. PubMed ID: 38383139
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant breast cancer: current perspectives.
Martin HL; Smith L; Tomlinson DC
Breast Cancer (Dove Med Press); 2014; 6():1-13. PubMed ID: 24648765
[TBL] [Abstract][Full Text] [Related]
12. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of IGF-1R expression during endocrine breast cancer treatment.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Koornstra RH; Linn SC; Oyen WJ; van der Graaf WT; van Laarhoven HW
Mol Imaging Biol; 2014 Aug; 16(4):529-37. PubMed ID: 24532107
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH; Uselman RR; Sachdev D; Yee D
Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
[TBL] [Abstract][Full Text] [Related]
15. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway.
Tufail M; Hu JJ; Liang J; He CY; Wan WD; Huang YQ; Jiang CH; Wu H; Li N
J Transl Med; 2024 Jan; 22(1):15. PubMed ID: 38172946
[TBL] [Abstract][Full Text] [Related]
16. Mutational Landscape and In-Silico Analysis of
Ahmad H; Ali A; Ali R; Khalil AT; Khan I; Khan MM; Alorini M
ACS Omega; 2023 Nov; 8(45):43318-43331. PubMed ID: 38024667
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic resistance to anti-oestrogen therapy in breast cancer.
Will M; Liang J; Metcalfe C; Chandarlapaty S
Nat Rev Cancer; 2023 Oct; 23(10):673-685. PubMed ID: 37500767
[TBL] [Abstract][Full Text] [Related]
18. Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.
Rosin J; Svegrup E; Valachis A; Zerdes I
Breast Cancer Res Treat; 2023 Sep; 201(2):161-169. PubMed ID: 37392328
[TBL] [Abstract][Full Text] [Related]
19. Computational estimation of quality and clinical relevance of cancer cell lines.
Trastulla L; Noorbakhsh J; Vazquez F; McFarland J; Iorio F
Mol Syst Biol; 2022 Jul; 18(7):e11017. PubMed ID: 35822563
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
